falsefalse

Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer - Episode 4

Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial

,

Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    x